Miopatía por cuerpos de inclusión. Caso clínico y revisión de la literatura

dc.creatorGuzmán V., Claudia M.
dc.creatorCubides, María F.
dc.creatorReyes S., Elsa
dc.creatorLondoño, John
dc.creatorSantos, Pedro
dc.creatorBautista, Wilson
dc.creatorSalazar, Rosa
dc.creatorVarela, Paola
dc.creatorValle O., Rafael
dc.date2010-06-30
dc.identifierhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1302
dc.identifier10.18359/rmed.1302
dc.descriptionLa miositis por cuerpos de inclusión (MCI) es una patología poco común que se presenta en individuos mayores de 50 años y con mayor frecuencia en hombres; sin embargo, los síntomas pueden empezar 20 años antes de su diagnóstico. Hasta un 30% de los casos de miopatías inflamatorias pueden ser de MCI y su prevalencia varía en los diferentes países y grupos étnicos. Clínicamente se manifiesta como debilidad lentamente progresiva proximal y distal. En este artículo se presenta un caso de una paciente de 78 años con antecedentes previos de diabetes mellitus tipo 2, hipertensión arterial, e hipotiroidismo, con cuadro de 18 meses de evolución consistente en debilidad de miembros inferiores, incapacidad para subir y bajar escaleras, limitación en la marcha, acompañado de disestesias. Se realizó la medición de la creatin quinasa (CK) y su valor inicial fue 7820, la electromiografía y neuroconducciones mostraron polineuropatia axonal motora en las cuatro extremidades y miopatía inflamatoria. Se trató con glucorticoides a dosis de 1 mg/kg y después de seis meses de tratamiento no se observó mejoría. Se decide tomar biopsia muscular que mostró miopatía por cuerpos de inclusión, lo que explicó la falla terapéutica inicial. Este caso es interesante desde el punto de vista clínico, ya que no es frecuente la elevación de la CK en los niveles que presentó la paciente y por las múltiples comorbilidades asociadas.
dc.formatapplication/pdf
dc.languagespa
dc.publisherUniversidad Militar Nueva Granada
dc.relationhttps://revistas.unimilitar.edu.co/index.php/rmed/article/view/1302/1033
dc.relation/*ref*/Amato A A, Gronseth G S, Jackson C E et al. Inclusion BodyMyositis: Clinical and Pathological Boundaries. Annals ofNeurology. 1996;40:581–6.
dc.relation/*ref*/Lotz B P, Engel A G, Nishino H et al. Inclusion Body Myositis:Observation in 40 Patients. Brain. 1989;112:727–47.
dc.relation/*ref*/Amato A A, Barohn R J. Inclusion Body Myositis: Old andNew Concepts. Journal of Neurology, Neurosurgery and Psychiatry.2009;80;1186-1193.
dc.relation/*ref*/Griggs R C, Askanas V, DiMauro S et al. Inclusion Body Myositisand Myopathies. Annals of Neurology. 1995;38:705-13
dc.relation/*ref*/Dalakas M C. Advance Online Publication. Nature ReviewsRheumatology. 2 February 2010.
dc.relation/*ref*/Chou S M. Myxovirus-like Structures in a Case of HumanChronic Polymyositis. Science. 1967;158:1453–55.
dc.relation/*ref*/Yunis E J, Samaha F J. Inclusion Body Myositis. LaboratoryInvestigation. 1971;25:240–48.
dc.relation/*ref*/Mendell J R, Sahenk Z, Gales T, Paul L. Amyloid Filaments inInclusion Body Myositis: Novel Findings Provide Insight intoNature of Filaments. Archives of Neurology. 1991;48:1229–34.
dc.relation/*ref*/Barohn R J, Amato A A. Inclusion Body Myositis. CurrentTreatment Options in Neurology. 2000;2:7–12.
dc.relation/*ref*/Vallejo G, Medina L F, Garcia L. Acta Médica Colombiana.2007;32(2).
dc.relation/*ref*/Askanas V, Engel WK. Inclusion Body Myositis: a MyodegenerativeConformational Disorder Associated with Aβ-Protein Misfolding, and Proteasome Inhibition. Neurology.2006;66:39–48.
dc.relation/*ref*/Dalakas M C. Sporadic Inclusion Body Myositis- Diagnosis,Pathogenesis, and Therapeutic Strategies. Nature ClinicalPractice. 2006;2:437–45.
dc.relation/*ref*/Griggs R C, Askansas V, DiMauro S et al. Inclusion Body Myositisand Myopathies. Annals of Neurolology. 1995;38:705–13.
dc.relation/*ref*/Dalakas M C, Illa I. Common Variable Immunodeficiency andInclusion Body Myositis: a Distinct Myopathy Mediated byNaturalkiller Cells. Annals of Neurology. 1995;37:806–10.
dc.relation/*ref*/Riggs J E, Schochet S S Jr, Gutmann L, McComas C F,RogersJ S 2nd. Inclusion Body Myositis and Chronic Immune,Thrombocytopenia. Archives of Neurology. 1984;41:93–95.
dc.relation/*ref*/Williams S F, Mincey B A, Calamia K T. Inclusion Body MyositisAssociated with Celiac Sprue and Idiopathic ThrombocytopenicPurpura. Southern Medical Journal. 2003;96:721–23.
dc.relation/*ref*/Kanellopoulos P, Baltoyiannis C, Tzioufas A G. PrimarySjögren’s Syndrome Associated with Inclusion Body Myositis.Rheumatology. 2002;41:440–44.
dc.relation/*ref*/Danon M J, Perurena O H, Ronan S, Manaligod J R. InclusionBody Myositis Associated with Systemic Sarcoidosis. CanadianJournal of Neurological Sciences. 1986;13:334–36.
dc.relation/*ref*/McCoy A L, Bubb M R, Plotz P H, Davis J C. Inclusion BodyMyositis Long after Dermatomyositis: a Report of Two Cases.Clinical and Experimental Rheumatology. 1999;17:235–39.
dc.relation/*ref*/Limaye V, Scott G, Kwiatek R, Pile K. Inclusion Body MyositisAssociated with Systemic Lupus Erythematosus. Australianand New Zealand Journal of Medicine. 2000;30:275–76.
dc.relation/*ref*/Kim S, Genth E, Krieg T, Hunzelmann N. PM-Scl AntibodyPositive Systemic Sclerosis Associated with Inclusion-BodyMyositis. Rheumatology. 2005;64:499–502.
dc.relation/*ref*/Dalakas M C, Illa I, Gallardo E, Juarez C. Inclusion BodyMyositis and Paraproteinemia: Incidence and ImmunopathologicCorrelations. Annals of Neurology. 1997;41:100–04
dc.relation/*ref*/Koff man B M, Rugiero M, Dalakas M C. Autoimmune Diseasesand Autoantibodies Associated with Sporadic InclusionBody Myositis. Muscle and Nerve. 1998;21:115–17.
dc.relation/*ref*/Cupler E J, Leon-Monzon M, Miller J, Semino-Mora C, AndersonTL, Dalakas M C. Inclusion Body Myositis in HIV-1and HTLV-1 Infected Patients. Brain. 1996;119:1887–93.
dc.relation/*ref*/Yakushiji Y, Satoh J, Yukitake M et al. Interferon Beta-ResponsiveInclusion Body Myositis in a Hepatitis C Virus Carrier.Neurology. 2004;63:587–88.
dc.relation/*ref*/Alexander J A, Huebner C J. Hepatitis C and InclusionBody Myositis. The Amercian Journal of Gastroenterology.1996;91:1845–47.
dc.relation/*ref*/Bouillot S, Coquet M, Ferrer X, Lagueny A, Leroy J P, VitalC.Inclusion Body Myositis Associated with Sacroidosis: A Reportof 3 Cases. Annals of Pathology. 2001;21:334–36.
dc.relation/*ref*/Mastaglia F L, Phillips BA. Idiopathic Infl ammatory Myopathies:Epidemiology, Classifi cation, and Diagnostic Criteria.Rheumatic Diseaseas Clinics of North America. 2002;28:723–41.
dc.relation/*ref*/Cherin P, Menard D, Mouton P et al. Macrophagic MyofasciitisAssociated with Inclusion Body Myositis: A Report of ThreeCases. Neuromuscular Disorders. 2001;11:452–57.
dc.relation/*ref*/Parissis D, Karkavelas G, Taskos N, Milonas I. Inclusion BodyMyositis in a Patient with a Presumed Diagnosis of Post-PolioSyndrome. Journal of Neurology. 2003;250:619–21.
dc.relation/*ref*/Lotz B P, Engel A G, Nishino H et al. Inclusion Body Myositis:Observation in 40 Patients. Brain. 1989;112:727–47.
dc.relation/*ref*/Mhiri C, Gherardi R. Inclusion Body Myositis in French Patients.A Clinicopathological Evaluation. Neuropathology andApplied Neurobiology. 1990;16:333–44.
dc.relation/*ref*/Badrising U A, Maat-Schieman M L, Van Houwelingen J Cet al. Inclusion Body Myositis: Clinical Features and ClinicalCourse of the Disease in 64 Patients. Journal of Neurology.2005;252:1448–54.
dc.relation/*ref*/Verma A, Bradley W G, Adesina A M et al. Inclusion BodyMyositis with Cricopharyngeus Muscle Involvement and SevereDysphagia. Muscle and Nerve. 1991;14:470–3.
dc.relation/*ref*/Darrow D H, Hoffman H T, Barnes GJ et al. Management ofDysphagia in Inclusion Body Myositis. Archives of Otolaryngology-Head and Neck Surgery. 1992;118:313–17.
dc.relation/*ref*/Eisen A, Berry K, Gibson G. Inclusion Body Myositis (IBM):Myopathy or Neuropathy? Neurology. 1983;33:1109–14.
dc.relation/*ref*/Joy J L, Oh S J, Baysal A I. Electrophysiological Spectrum ofInclusion Body Myositis. Muscle Nerve. 1990;13:949–51.
dc.relation/*ref*/Lotz B P, Engel A G, Nishino H. Inclusion Body Myositis: Observationin 40 Patients. Brain. 1989;112:727-47.
dc.relation/*ref*/Griggs R C, Askansas V, DiMauro S et al. Inclusion Body Myositisand Myopathies. Annals of Neurology. 1995;38:705-13.
dc.relation/*ref*/Koffman B M, Rugiero M, Dalakas MC. Immune-MediatedConditions and Antibodies Associated with Sporadic InclusionBody Myositis. Muscle Nerve. 1998;21:115-17.
dc.relation/*ref*/Love L A, Leff R L, Fraser D. A New Approach to the Classificationof Idiopathic Inflammatory Myopathy: Myositis-SpecificAutoantibodies Define Useful Homogeneous Patient Groups.Medicine (Baltimore). 1991;70:360–74.
dc.relation/*ref*/Fraser D D, Frank J A, Dalakas M. Magnetic Resonance Imagingin the Idiopathic Inflammatory Myopathies. The Journalof Rheumatology. 1991;18:1693-700.
dc.relation/*ref*/Sekul E A, Chow C, Dalakas M C. Magnetic Resonance Imagingof the Forearm as a Diagnostic Aid in Patients with SporadicInclusion Body Myositis. Neurology. 1993;48:863–6.
dc.relation/*ref*/Lacomis D. Neurophatic Disorders and Muscular Dystrophy.In Worthmann R L. Disease of Skeletal Muscle. Philadelphia.Lippincott, Williams and Milkins. 2000:197-220.
dc.relation/*ref*/Rudnicki S A, Dalmau J. Paraneoplastic Syndromes ofthe Spinal Cord, Nerve, and Muscle Nerve. Muscle Nerve.2000;23:1800-18.
dc.relation/*ref*/Griggs R C, Askansas V, DiMauro S. Inclusion Body Myositisand Myopathies. Annals of Neurology. 1995;38:705–13.
dc.relation/*ref*/Barohn R J, Amato A A, Sahenk Z, Kissel J T, Mendell J R.Inclusion Body Myositis: Explanation for Poor Response toImmunosuppressive Therapy. Neurology. 1995;45:1302–04.
dc.relation/*ref*/Askanas V, McFerrin J, Alvarez R B, Baque S, Engel W K.βAPP Gene Transfer into Cultured Human Muscle InducesInclusion Body Myositis Aspects. NeuroReport. 1997; 8:2155–58.
dc.relation/*ref*/Badrising U A, Maat-Schieman M L, Ferrari M D. Comparisonof Weakness Progression in Inclusion Body Myositis duringTreatment with Methotrexate or Placebo. Annals of Neurology.2002;51:369–72.
dc.relation/*ref*/Leff R L, Miller F W, Hicks J, Fraser D D, Plotz P H. TheTreatmentof Inclusion Body Myositis: A Retrospective Reviewand a Randomized, Prospective Trial of ImmunosuppressiveTherapy. Medicine. 1993;72:225–35.
dc.relation/*ref*/Soueidan SA, Dalakas MC. Treatment of Inclusion-Body Myositiswith High-Dose Intravenous Immunoglobulin. Neurology.1993;4:876-9.
dc.relation/*ref*/Amato A A, Barohn R J, Jackson C E, Pappert E J, SahenkZ, Kissel J T. Inclusion Body Myositis: Treatment with IntravenousImmunoglobulin. Neurology. 1994;444:1516–18.
dc.relation/*ref*/Lindberg C, Trysberg E, Tarkowski A, Oldfors A. Anti-T LymphocyteGlobulin Treatment in Inclusion Body Myositis. Neurology.2003;61:260–62.
dc.relation/*ref*/Group TMS. Randomized Pilot trial of Beta INF1a (Avonex)in Patients with Inclusion Body Myositis. Neurology.2001;57:1566–70.
dc.relation/*ref*/Group TMS. Randomized Pilot Trial of High-Dose INF-1a inPatients with Inclusion Body Myositis. Neurology. 2004; 63:718–20.
dc.relation/*ref*/Barohn R J, Herbelin L, Kissel J T. Pilot Trial of Etanerceptin the Treatment of Inclusion Body Myositis. Neurology.2006;66:123–24.
dc.relation/*ref*/Rose J W et al. Daclizumab Phase II Trial in Relapsing andRemitting Multiple Sclerosis: MRI and Clinical Results. Neurology.2007;69:785–789.
dc.relation/*ref*/Dalakas M C et al. Effect of Alemtuzumab (CAMPATH 1‑H) inPatients with Inclusion Body Myositis. Brain. 2009;132:1536–1544.
dc.relation/*ref*/O’Connor P et al. Oral Fingolimod (FTY720) in Multiple Sclerosis:Two‑year Results of a Phase II Extension Study. Neurology.2009;72:73–79.
dc.relation/*ref*/Kissel J T, Mendell J R, Rammohan K W. Microvascular Depositionof Complement Membrane Attack Complex in Dermatomyositis.New England Journal of Medicine. 1986;314:329–334.
dc.relation/*ref*/Dalakas M C. B Cells as Therapeutic Targets in AutoimmuneNeurological Disorders. Nature Clinical Practice Neurology.2008;4:557–567.
dc.relation/*ref*/Basta M, Dalakas M C. High‑Dose Intravenous ImmunoglobulinExerts, its Beneficial Effect in Patients with Dermatomyositisby Blocking Endomysial Deposition of Activated ComplementFragments. The Journal of Clinical Investigation.1994;94 :1729-35.
dc.relation/*ref*/Cherin P, Pelletier S, Teixeira A. Intravenous Immunoglobulinfor Dysphagia of Inclusion Body Myositis. Neurology.2002;58:326-7.
dc.relation/*ref*/Darrow D H, Hoff man H T, Barnes G J, Wiley C A. Managementof Dysphagia in Inclusion Body Myositis. Archives ofOtolaryngology- Head and Neck Surgery. 1992;118:313–17.
dc.relation/*ref*/Liu L W, Tarnopolsky M, Armstrong D. Injection of BotulinToxic A to the Upper Esophageal Sphincter for OropharyngealDysphagia in two Patients with Inclusion Body Myositis. TheCanadian Journal of Gastroenterology. 2004;18:397–99.
dc.relation/*ref*/Arnardottir S, Alexanderson H, Lundberg I E, Borg K. SporadicInclusion Body Myositis: Pilot Study on the Eff ects of aHome Exercise Program on Muscle Function, Histopathologyand Infl ammatory Reaction. Journal of Rehabilitation Medicine.2003;35:31–35.
dc.relation/*ref*/Heikkila S, Vittanen J V, Kautianen H. Rehabilitation in Myositis.Physiotherapy. 2001;87:301-09.
dc.relation/*ref*/Spector S A, Lemmer J T, Koff man B M. Safety and Efficacyof Strength Training in Patients with Sporadic Inclusion BodyMyositis. Muscle Nerve. 1997;20:1242-48.
dc.relation/*ref*/Waclawik A J, Rao V K. Effective Treatment of Severe FingerFlexion Weakness in Inclusion Body Myositis Using TendonTransfers. Journal of Clinical Neuromuscular Disease.2002;4:31-32.
dc.relation/*ref*/Rutkove S B, Parker R A, Nardin R A. A Pilot RandomizedTrial of Oxandrolone in Inclusion Body Myositis. Neurology.2002;58:1081–87.
dc.rightsDerechos de autor 2015 Revista Med
dc.sourceRevista Med; Vol. 18 No. 1 (2010): january - june; 93-99
dc.sourceRevista Med; Vol. 18 Núm. 1 (2010): enero - junio; 93-99
dc.source1909-7700
dc.source0121-5256
dc.subjectmiositis
dc.subjectmiopatía
dc.subjectcuerpos de inclusión
dc.titleMiopatía por cuerpos de inclusión. Caso clínico y revisión de la literatura
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución